Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.49 |
| ▸ | CTSS | P25774 | 4/20 | 0.44 |
| ▸ | CTSV | O60911 | 3/20 | 0.44 |
| ▸ | CTSL | P07711 | 3/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7014847 | 0.95 | CTSK (0.44) | CTSKCTSSCTSVCTSLNPC1 | |
| SCHEMBL4452707 | 0.92 | CTSK (0.50) | CTSKCTSSCTSVCTSLRAB9A | |
| SCHEMBL4452610 | 0.91 | CTSK (0.49) | CTSKCTSSCTSVCTSLNPC1 | |
| SCHEMBL4451610 | 0.91 | CTSS (0.55) | CTSKCTSSCTSVCTSLNPC1 | |
| SCHEMBL4452668 | 0.90 | CTSK (0.62) | CTSKCTSSCTSVCTSLNPC1 | |
| SCHEMBL4446769 | 0.89 | CTSS (0.44) | CTSKCTSSCTSVCTSLNPC1 | |
| SCHEMBL7018355 | 0.89 | CTSK (0.52) | CTSKCTSSCTSVCTSL | |
| SCHEMBL4459438 | 0.89 | CTSK (0.48) | CTSKCTSSCTSVCTSLNPC1 | |
| SCHEMBL4458891 | 0.88 | CTSK (0.49) | CTSKCTSSCTSVCTSL | |
| SCHEMBL4457938 | 0.87 | CTSS (0.47) | CTSKCTSSCTSVCTSLNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD. (GB) | 2009-10-01 | — | — | US | disclosed |
| US-7425562-B2 | Inhibitors of cruzipain and other cysteine proteases | AMURA THERAPEUTICS LTD. (GB) | 2008-09-16 | — | — | US | disclosed |
| EP-1362052-B1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2007-03-07 | — | — | EP | disclosed |
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | GRUNENTHAL GMBH (DE) | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138250-A1 | Inhibitors of cruzipain and other cysteine proteases | CPN1, CTRL, CPA1 | CTSK 62/4885CTSS 39/4885CTSV 27/4885 |
| US-20090247471-A1 | INHIBITORS OF CRUZIPAIN AND OTHER CYSTEINE PROTEASES | CPN1, CTRL, CPA1 | CTSK 45/4885CTSS 21/4885CTSV 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.